Titan Medical Appoints Bill Fahey as Vice President, Manufacturing and Operations
06 June 2022 - 9:30PM
Titan Medical Inc. (Nasdaq:
TMDI; TSX: TMD),
a medical device company focused on the development and
commercialization of innovative surgical technologies for single
access robotic-assisted surgery (RAS), today announced the
appointment of Bill Fahey as Vice President, Manufacturing and
Operations. In this new role, Mr. Fahey will be a key member of the
senior leadership team and be responsible for both in-house and
contract manufacturing relationships. He will also be working
closely with Titan’s product development and the quality and
regulatory affairs teams as the company completes its
Investigational Device Exemption (IDE) application and, following
IDE approval, proceed to human clinical trials.
“Bill brings the necessary skills, experience and energy to our
Chapel Hill operations to get the Enos project across the line,”
stated Paul Cataford, Interim President, CEO and Board Chair. “We
remain focused on our IDE application and Bill brings a track
record of successful operations leadership to ensure we meet our
goals on-time and with excellence.”
Mr. Fahey brings more than 20 years of product development,
manufacturing and commercialization experience in the medical
device industry. Mr. Fahey has been responsible for creating and
leading product development engineering teams and processes to meet
regulatory requirements, execute on strategy and foster
cross-functional efficiency and accountability. Most recently, he
served as Senior Vice President of Engineering at Precision
Spine/Spinal USA, a spinal implant company where he drove multiple
product releases and line extensions that were manufactured
in-house. Before joining Precision Spine, Bill spent over five
years with Orthofix/Blackstone Medical Inc. as Sr. Director of
Engineering. He also held a product development position in
Stryker's Spine division. Mr. Fahey holds a Bachelor of Science
Degree in Mechanical Engineering from Villanova University.
"I am excited to join Titan Medical at such a transformational
time. My work over the past two decades has prepared me for this
position with Titan and I look forward to applying my background
and experience as the company prepares for clinical trials and
progresses to commercial production," said Mr. Fahey.
About Titan Medical
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device
company headquartered in Toronto, Ontario and with operations in
Chapel Hill, North Carolina, is focused on enhancing robotic
assisted surgery using innovative technology through a single
access point. The Enos™ robotic single access surgical system is
being developed with an ergonomic focus to provide a surgical
experience that imitates real-life movements that surgeons demand
and includes multi-articulating instruments designed to allow
surgeons an increased range of motion in a confined space, with
dexterity and the ability to exert the forces necessary to complete
common surgical tasks. With the Enos system, Titan intends to
initially pursue gynecologic surgical indications.
Enos™ is a trademark of Titan Medical Inc.
For more information,
visit www.titanmedicalinc.com and
follow @TitanMedical on Twitter and LinkedIn.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws, which
reflect the current expectations of management of the company’s
future growth, results of operations, performance, and business
prospects and opportunities. Wherever possible, words such as
“may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements, including, without limitation, references to: the
company’s focus on the design and development of surgical
technologies for robotic single access surgery; the company’s
intention to complete an IDE application and, following IDE
approval, proceed to human clinical trials; the Enos system
providing a surgical experience that imitates real-life movements;
and the company’s intention to initially pursue gynecologic
surgical indications with the Enos system. These statements reflect
management’s current beliefs and are based on information currently
available to management. Forward-looking statements involve
significant risks, uncertainties and assumptions. Many factors
could cause the company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the company’s Annual
Report on Form 20-F for the fiscal year ended December 31, 2021,
which may be viewed at www.sedar.com and at www.sec.gov. Should one
or more of these risks or uncertainties materialize, or should
assumptions underlying the forward-looking statements prove
incorrect, actual results, performance, or achievements may vary
materially from those expressed or implied by the forward-looking
statements contained in this news release. These factors should be
considered carefully, and prospective investors should not place
undue reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable
assumptions, the company cannot assure prospective investors that
actual results, performance or achievements will be consistent with
these forward-looking statements. Except as required by law, the
company expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information, future events or otherwise.
ContactKristen GalfettiVice President, Investor
Relations & Corporate
Communications+1-781-869-2553investors@titanmedicalinc.com
###
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Apr 2024 to May 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From May 2023 to May 2024